NCT07472868 2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3 Not yet recruiting
Clinical Trials
22 trialsNCT07412613 2026-02-27
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Akeso
Phase 3 Not yet recruiting
NCT07409428 2026-02-13
A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Not yet recruiting
NCT07113275 2026-02-12
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Not yet recruiting
NCT05700448 2026-02-05
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
CStone Pharmaceuticals
Phase 3 Not yet recruiting
NCT07385703 2026-02-04
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT07340567 2026-01-14
CIRCULATEIII
UNICANCER
Phase 3 Not yet recruiting
NCT07328919 2026-01-09
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
TransThera Sciences (Nanjing), Inc.
Phase 3 Not yet recruiting
NCT06093425 2025-12-17
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 3 Not yet recruiting
NCT07277842 2025-12-11
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06783491 2025-11-24
FOXHIPECT4
Maimónides Biomedical Research Institute of Córdoba
Phase 3 Not yet recruiting
NCT07155629 2025-09-04
LEFT-PANC
Helsinki University Central Hospital
Phase 3 Not yet recruiting
NCT07132008 2025-08-20
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 3 Not yet recruiting
NCT07025239 2025-06-17
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06899477 2025-03-28
Pre-Operative Treatment in REseCTable COlon CanceR
Charite University, Berlin, Germany
Phase 3 Not yet recruiting
NCT06571461 2024-08-27
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06411171 2024-05-17
Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:
Xijing Hospital of Digestive Diseases
Phase 3 Not yet recruiting
NCT06217042 2024-01-22
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
Fudan University
Phase 3 Not yet recruiting
NCT05914610 2023-08-25
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
Fujian Medical University
Phase 3 Not yet recruiting
NCT05699746 2023-01-26
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
Zhejiang University
Phase 3 Not yet recruiting
NCT05427669 2022-10-07
AFFORD
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT03961841 2019-12-23
Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Not yet recruiting